PRESS RELEASE
Change in the management of InfectoPharm
The German pacesetter in pediatrics and infectiology further expands international activities
Heppenheim, May 9, 2023 – InfectoPharm Arzneimittel und Consilium GmbH welcomed Dr. Aldo Ammendola (53) to the four-member executive management team of the expanding Hessian company on May 1, 2023. The medium-sized pharmaceutical company is German leader in the field of pediatrics and focusses on unique antibiotic treatment options. A leaving ceremony was held for his predecessor, Dr. Norbert Stempel, on April 28, 2023, after 20 successful years on the Board of Management and close to 30 years with the company. Dr. Ammendola, previously Co-CEO/Chief Research & Development Officer of Weleda AG (Arlesheim, Switzerland), will take over the Research, Development and Manufacturing division.
“Growing means internationalization,” is the firm conviction of Ammendola with his 20+ years background in drug development. “I look forward to taking InfectoPharm’s first-class infectious disease and pediatric product portfolio into new markets. And, of course, we will continue to expand the pipeline.” A considerable list of projects is already planned or in the process of being implemented. Particularly when it comes to developing and optimizing pharmaceuticals, Ammendola points to his previous career successes. In addition to pharmaceuticals, these also include other promising product categories, such as medical devices, cosmetics, and dietary supplements.
The InfectoPharm Group, which operates throughout Europe, achieves an average annual growth rate of 15 percent and sales of around 250 million euros, of which the international business unit accounts for around 25 percent.
Ammendola is looking forward to contributing to the further transformation of the InfectoPharm Group towards even more internationality: “Creating a shared identity while integrating the local cultures will be an interesting challenge in the next ten to 20 years”.
He is optimistic about the future of InfectoPharm. And this is not only due to the forward-looking business model, but above all to the hands-on approach of the medium-sized company: “We don’t complain because everything is becoming so difficult. We don’t hesitate, we take advantage of opportunities, we are fast, and we are becoming more and more visible in the industry and relevant markets with our clear stance. This will help us to set up new long-term partnerships.”
Dr. Norbert Stempel worked for InfectoPharm since 1990 (with one interruption), helping to shape the company’s fortunes for almost all of its 35-year history. He was a member of the management team since 2003, initially as authorized signatory responsible for Marketing & Sales, then from 2013 as Managing Director Head of Research & Manufacturing. “Dr. Stempel has made a significant contribution to the structured and successful development of our company,” commented Philipp Zöller, Chairman of the Board. “On behalf of my family, I would like to thank him for all his input and the many essential projects, studies and approvals of important and unique preparations he has seen through to successful completion.”
Vita Dr. Aldo Ammendola
After holding an assistant professorship at the Technical University of Munich, Dr. Aldo Ammendola, who holds a doctorate in micro- and molecular biology, embarked on a management career at 4SC AG, Munich-Martinsried, and Capgemini Strategy Consulting, Stuttgart. After a period abroad in the USA, Ammendola took on management positions again at 4SC (Strategic Planning & Regulatory Affairs), at Bionorica SE, Neumarkt (Research and Development), and most recently as Managing Director Research & Development at Weleda AG, Arlesheim/Switzerland, a company specializing in natural cosmetics and natural medicine.
The InfectoPharm Board of Management as of May 2023
Philipp Zöller – Chairman of the Board/Business Development (pharmacist)
Michael Gilster – Commercial Field/Logistics/IT (industrial engineer)
Dr. Markus Rudolph – Marketing/Sales/International business/Communication (pharmacist)
Dr. Aldo Ammendola – Research/Development/Manufacturing (biologist)
Web link
To the InfectoPharm website
_____________________________________________________
About InfectoPharm
InfectoPharm Arzneimittel und Consilium GmbH is Germany’s leading pharmaceutical company, especially for pediatrics and infectiology. For over 30 years, this medium-sized company has distinguished itself as a groundbreaking pioneer in various fields of indications. The portfolio currently comprises around 130 preparations with numerous innovations in the fields of pediatrics, dermatology, infectious diseases, pneumology and allergology, which are increasingly attracting international attention. The “consilium service” is available free of charge to specialists as a product-neutral advisory and knowledge transfer service.
The InfectoPharm Group is engaged in more than 30 international partnerships and is increasingly expanding into non-EU markets. Subsidiaries of the group in Austria and Italy operate with a selected part of the portfolio. The InfectoPharm Group further consists of two strategically matching German subsidiaries. Pädia GmbH offers a distinct pediatric OTC portfolio with about 25 prescription-free pharmaceuticals and Beyvers GmbH in Berlin is an internationally known full service-supplier for pharmaceuticals and cosmetics.
With more than 350 employees, the group generates annual sales of around 250 million euros (2022) and an average growth rate of 15 percent. InfectoPharm regularly receives awards from the medical profession, such as the “Golden Tablet” or currently as “Most Crisis-Proof Employer” from Creditreform.
